Tanja Trarbach

Bavarian Academy of Sciences and Humanities — Germany

Medicine · Health Sciences

28h-index3.8kcitations136works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(68), Gastric Cancer Management and Outcomes(37), Cancer Treatment and Pharmacology(31), Lung Cancer Treatments and Mutations(20), Cholangiocarcinoma and Gallbladder Cancer Studies(19)

Publications132 total

Evaluation of the Socio-Medical Assessment of Work Capacity in Patients with Colorectal Cancer in German Rehabilitation Clinics: Its Diagnostic Accuracy for Actual Return to Work and the Physicians’ Views on Potential Changes in Current Practice
Journal of Occupational Rehabilitation·2025Open Access
Evaluation of the Socio-Medical Assessment of Work Capacity in Patients with Colorectal Cancer in German Rehabilitation Clinics: Its Diagnostic Accuracy for Actual Return to Work and the Physician’s Views on Potential Changes in Current Practice
2025Open Access
Prognostic and predictive impact of the baseline systemic proteome in patients with <i>RAS</i> wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial.
Journal of Clinical Oncology·2025
Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212).
Journal of Clinical Oncology·2022
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).
Journal of Clinical Oncology·2021· 1 cited
Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial
Radiation Oncology·2021· 12 citedOpen Access
438P Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
Annals of Oncology·2020· 1 citedOpen Access
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
Clinical Colorectal Cancer·2020· 8 cited
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).
Journal of Clinical Oncology·2019· 1 cited
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project
Breast Cancer Research and Treatment·2019· 25 citedOpen Access
Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (<scp>mCCS</scp>)
Colorectal Disease·2019· 6 citedOpen Access
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
Leukemia Research·2018· 6 cited
AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
Oncotarget·2017· 14 citedOpen Access
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
BMC Cancer·2017· 26 citedOpen Access
Molecular dissection of effector mechanisms of <i>RAS</i>-mediated resistance to anti-EGFR antibody therapy
Oncotarget·2017· 14 citedOpen Access
A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)
Journal of Cancer Research and Clinical Oncology·2016· 16 citedOpen Access
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
Annals of Oncology·2016· 28 citedOpen Access
Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RAS WT metastatic colorectal cancer
Annals of Oncology·2016· 1 citedOpen Access
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR
Annals of Oncology·2016· 1 cited
Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial
Annals of Oncology·2016· 1 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Dirk Laurent(9), U. Vanhoefer(8), Florian Lordick(7), Gunnar Folprecht(6), Andreas Paul(6), N. Schleucher(5), Salah‐Eddin Al‐Batran(5), Georgios C. Sotiropoulos(5), J.T. Hartmann(4), Hans‐Joachim Schmoll(4), George Sgourakis(4), Markus Moehler(4), Henning Reis(4), Martin Schüler(4), David Malka(3), Christelle de la Fouchardière(3), Éveline Boucher(3), Lætitia Fartoux(3), F. Viret(3), Eric Assénat(3)